Asymchem Laboratories (Tianjin) Co., Ltd. Class H (HK:6821)
:6821
6821 Stock Chart & Stats
HK$73.80
-HK$0.50(-1.06%)
At close: 4:00 PM EST
HK$73.80
-HK$0.50(-1.06%)
Day’s Range― - ―
52-Week RangeHK$41.95 - HK$116.60
Previous CloseN/A
Volume191.84K
Average Volume (3M)640.69K
Market Cap
HK$48.78B
Enterprise ValueHK$34.32B
Total Cash (Recent Filing)HK$7.44B
Total Debt (Recent Filing)HK$256.47M
Price to Earnings (P/E)20.0
Beta1.44
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.57%
Share Statistics
EPS (TTM)0.52
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$119.32Price Target Upside61.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.36
Revenue Forecast (FY)HK$9.11B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and a capital base dominated by equity provide durable financial flexibility. This reduces refinancing risk, supports counter-cyclical investment into capacity or quality systems, and lets management pursue multi-year CDMO contracts without being constrained by leverage.
Solid Profit MarginsSustained gross (~42%) and net (~16%) margins indicate structural manufacturing efficiencies and pricing power in CDMO services. Such margin durability supports reinvestment in GMP capacity and quality, funds organic growth, and underpins long-term return generation even if top-line growth slows.
CDMO Model With Recurring Supply PotentialAs a CDMO providing development-to-commercial services, the firm can convert successful development projects into recurring commercial supply agreements. This creates durable, sticky customer relationships and revenue streams that improve long-term predictability once drugs reach commercialization.
Bears Say
Volatile Free Cash FlowInconsistent free cash flow undermines the firm’s ability to self-fund capacity expansion, sustain dividends, or pursue strategic M&A. For a capital-intensive CDMO, uneven FCF increases reliance on external financing and can constrain long-term capacity planning and competitive responsiveness.
Choppy Revenue GrowthIntermittent top-line declines reflect project timing, customer sequencing or demand variability. This makes capacity utilization and multi-year planning harder, increases cyclicality in margins and FCF, and raises execution risk when scaling facilities for longer-term commercial contracts.
Earnings Reset From Peak YearsA post-peak reset suggests prior outperformance was at least partly cyclical or one-off. If higher margins are not sustainable, future returns may be structurally lower and management must deliver operational improvements or higher mix of commercial supply to restore prior profitability levels.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H News
6821 FAQ
What was Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price range in the past 12 months?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H lowest stock price was HK$41.95 and its highest was HK$116.60 in the past 12 months.
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap is HK$48.78B.
When is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date is Apr 28, 2026 which is in 17 days.
How were Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s earnings last quarter?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported HK$0.522 earnings per share for the quarter, beating the consensus estimate of HK$0 by HK$0.522.
Is Asymchem Laboratories (Tianjin) Co., Ltd. Class H overvalued?
According to Wall Street analysts Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price is currently Undervalued.
Does Asymchem Laboratories (Tianjin) Co., Ltd. Class H pay dividends?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H pays a Annually dividend of HK$1.202 which represents an annual dividend yield of 1.57%. See more information on Asymchem Laboratories (Tianjin) Co., Ltd. Class H dividends here
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Asymchem Laboratories (Tianjin) Co., Ltd. Class H have?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H has 27,834,510 shares outstanding.
What happened to Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price movement after its last earnings report?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H reported an EPS of HK$0.522 in its last earnings report, beating expectations of HK$0. Following the earnings report the stock price went up 0.502%.
Which hedge fund is a major shareholder of Asymchem Laboratories (Tianjin) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6821
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.63%
12-Months-Change
Fundamentals
Return on Equity
6.54%
Trailing 12-Months
Asset Growth
11.04%
Trailing 12-Months
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) Earnings & Revenues
6821 Stock 12 Month Forecast
Average Price Target
HK$119.32
▲(61.67% Upside)
Technical Analysis
Genscript Biotech
―
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---